The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
In vitro blocking of IL-2 binding: Use at an assay dependent dilution.
FACS: Use 0.3µg for 106 cells.
IP: Use at an assay dependent dilution.
Inhibition of IL-2 or mitogen-induced T cell proliferation: Use at an assay dependent dilution.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Receptor for interleukin-2.
Involvement in disease
Genetic variations in IL2RA are associated with susceptibility to diabetes mellitus insulin-dependent type 10 (IDDM10) [MIM:601942]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
References for Anti-IL2 Receptor alpha antibody [3C7] (Phycoerythrin) (ab25512)
This product has been referenced in:
Lorenzo F et al. Structure-function study of the p55 subunit of murine IL-2 receptor by epitope mapping. J Immunol147:2970-7 (1991).
Read more (PubMed: 1717581) »
Moreau JL et al. Monoclonal antibodies identify three epitope clusters on the mouse p55 subunit of the interleukin 2 receptor: relationship to the interleukin 2-binding site. Eur J Immunol17:929-35 (1987).
Read more (PubMed: 2440696) »